TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications
TC BioPharm (NASDAQ: TCBP) has been granted a European patent for the use of modified gamma delta cells in treating cancer and viral indications. This patent expands TCBP's portfolio and aligns with their commercial strategy. CEO Bryan Kobel emphasized the company's focus on TCB008 applications while developing future high-value gamma delta assets for indications like solid tumors.
Kobel highlighted the potential of modified gamma delta t-cells to outperform current CAR and modified t-cells in terms of safety and efficacy. The patent protection is seen as creating a competitive advantage and adding value in potential acquisition scenarios.
TC BioPharm (NASDAQ: TCBP) ha ricevuto un brevetto europeo per l'uso di cellule gamma delta modificate nel trattamento di tumori e indicazioni virali. Questo brevetto amplia il portafoglio di TCBP e si allinea con la loro strategia commerciale. Il CEO Bryan Kobel ha sottolineato l'attenzione dell'azienda sulle applicazioni di TCB008 mentre sviluppa futuri asset gamma delta ad alto valore per indicazioni come tumori solidi.
Kobel ha evidenziato il potenziale delle cellule t gamma delta modificate di superare le attuali cellule CAR e le cellule t modificate in termini di sicurezza e efficacia. La protezione brevettuale è vista come un vantaggio competitivo e come un valore aggiunto in scenari di potenziali acquisizioni.
TC BioPharm (NASDAQ: TCBP) ha recibido una patente europea para el uso de células gamma delta modificadas en el tratamiento de cáncer y indicaciones virales. Esta patente amplía la cartera de TCBP y se alinea con su estrategia comercial. El CEO Bryan Kobel destacó el enfoque de la empresa en las aplicaciones de TCB008 mientras desarrolla futuros activos gamma delta de alto valor para indicaciones como tumores sólidos.
Kobel subrayó el potencial de las células T gamma delta modificadas para superar las actuales células CAR y las células T modificadas en términos de seguridad y eficacia. La protección de la patente se considera como una ventaja competitiva y un valor añadido en escenarios de posibles adquisiciones.
TC BioPharm (NASDAQ: TCBP)는 암 및 바이러스 질환 치료를 위한 변형 감마 델타 세포 사용에 대한 유럽 특허를 획득했습니다. 이 특허는 TCBP의 포트폴리오를 확대하고, 상업적 전략과 일치합니다. CEO 브라이언 코벨은 TCB008 응용 프로그램에 대한 회사의 초점을 강조하며, 고부가가치 감마 델타 자산을 고형 종양과 같은 적응증에 대해 개발하고 있습니다.
코벨은 변형된 감마 델타 T세포가 현재의 CAR 및 변형 T세포를 능가할 수 있는 잠재력을 가지고 있다고 강조했습니다. 특허 보호는 경쟁 우위를 창출하고 잠재적인 인수 시나리오에서 가치를 추가하는 것으로 여겨집니다.
TC BioPharm (NASDAQ: TCBP) a obtenu un brevet européen pour l'utilisation de cellules gamma delta modifiées dans le traitement du cancer et des indications virales. Ce brevet élargit le portefeuille de TCBP et s'aligne avec leur stratégie commerciale. Le PDG Bryan Kobel a souligné l'accent mis par l'entreprise sur les applications de TCB008 tout en développant de futurs actifs gamma delta à forte valeur ajoutée pour des indications telles que tumeurs solides.
Kobel a mis en avant le potentiel des cellules T gamma delta modifiées pour dépassement des cellules CAR et des cellules T modifiées actuelles en termes de sécurité et d'efficacité. La protection par brevet est vue comme créant un avantage concurrentiel et ajoutant de la valeur dans des scénarios d'acquisition potentiels.
TC BioPharm (NASDAQ: TCBP) hat ein europäisches Patent für die Verwendung von modifizierten Gamma-Delta-Zellen zur Behandlung von Krebs und viralen Indikationen erhalten. Dieses Patent erweitert das Portfolio von TCBP und steht im Einklang mit ihrer Geschäftsstrategie. CEO Bryan Kobel betonte den Fokus des Unternehmens auf die Anwendungen von TCB008, während zukünftige hochgradige Gamma-Delta-Vermögenswerte für Indikationen wie solide Tumoren entwickelt werden.
Kobel hob das Potenzial modifizierter Gamma-Delta-T-Zellen hervor, aktuelle CAR- und modifizierte T-Zellen in Bezug auf Sicherheit und Wirksamkeit zu übertreffen. Der Patentschutz wird als Schaffung eines Wettbewerbsvorteils angesehen und steigert den Wert in potenziellen Akquisitionsszenarien.
- Granted European patent for modified gamma delta cells in cancer and viral treatment
- Expansion of patent portfolio strengthens competitive position
- Potential for modified gamma delta t-cells to outperform current CAR and modified t-cells in safety and efficacy
- Patent protection adds value for potential acquisition scenarios
- None.
Insights
This patent grant significantly bolsters TC BioPharm's intellectual property portfolio in the competitive field of cell therapies. The broad coverage for modified gamma delta cells in both cancer and viral indications provides TCBP with a strong market position in Europe. This could potentially:
- Attract partnerships or licensing deals with larger pharmaceutical companies
- Increase the company's valuation in case of a potential acquisition
- Provide a competitive edge in developing next-generation cell therapies
However, it's important to note that while patents are valuable assets, they don't guarantee clinical success or market approval. Investors should closely monitor TCBP's clinical progress, particularly with TCB008, to assess the real-world potential of this intellectual property.
The patent's coverage of modified gamma delta cells for cancer treatment is particularly intriguing. These cells have shown promise in preclinical studies due to their unique properties:
- Ability to recognize and target a broad range of cancer cells
- Potential for reduced risk of graft-versus-host disease compared to alpha-beta T cells
- Capacity to infiltrate solid tumors, a major challenge in current cell therapies
If TCBP can successfully translate these advantages into clinical outcomes, it could potentially address some limitations of current CAR-T therapies. However, the road from patent to approved therapy is long and uncertain. Investors should watch for upcoming clinical trial results to gauge the true potential of this technology.
The Company intends to proceed with the patent process in specific European countries in line with the commercial strategy of TCBP.
"We are pleased to further expand our patent portfolio at TCBP with this European patent for Modified Gamma Delta t-cells" said Bryan Kobel, CEO of TC BioPharm. "TCBP continues to focus on our immediate applications for TCB008 while developing future high value gamma delta assets for other indications such as solid tumors. We believe gamma deltas can be a high impact therapeutic when modified with the potential to outpace current CAR and modified t-cells in safety and efficacy, patent protecting these approaches gives us a competitive moat and further value in a potential acquisition scenario."
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this press release. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-announces-grant-of-european-patent-covering-use-of-modified-gamma-delta-cells-for-the-treatment-of-cancer-and-viral-indications-302233266.html
SOURCE TC BioPharm
FAQ
What patent did TC BioPharm (TCBP) recently receive from the European Patent Office?
How does the new European patent align with TC BioPharm's (TCBP) strategy?
What potential advantages does TC BioPharm (TCBP) see in modified gamma delta t-cells?
How does the new patent impact TC BioPharm's (TCBP) position in potential acquisition scenarios?
